Jamming bacterial communication: new approaches for the treatment of infectious diseases.
The global rise of anti-microbial resistance, combined with the rapid rate of microbial evolution, and the slower development of novel antibiotics, underscores the urgent need for innovative therapeutics. We are facing a post-antibiotic era with a decreased armamentarium to combat infectious diseases. Development of novel drugs will rely on basic research aimed to increase our understanding of bacterial pathogenesis and the inter-cellular chemical signalling among bacterial cells. Such basic science, when combined with contemporary drug discovery technologies, may be translated into therapeutic applications to combat bacterial infections. In this review, we discuss many strategies aimed to interfere with bacterial cell-to-cell signalling via the quorum-sensing (QS) pathway to inhibit bacterial virulence and/or the development of microbial communities (known as biofilms), which are refractory to antibiotic treatment. QS antagonists should be viewed as blockers of pathogenicity rather than as anti-microbials and because QS is not involved in bacterial growth, inhibition of QS should not yield a strong selective pressure for development of resistance. QS inhibitors (QSIs) hold great expectations and we look forward to their application in fighting bacterial infections.
Njoroge
Jacqueline
J
Department of Microbiology, UT Southwestern Medical Center, Dallas, TX, USA.
Sperandio
Vanessa
V
D001419:Bacteria / Q000187:drug effects* / Q000378:metabolism* / Q000472:pathogenicity; D001424:Bacterial Infections / Q000188:drug therapy*; D054324:Enterohemorrhagic Escherichia coli / Q000187:drug effects / Q000378:metabolism / Q000472:pathogenicity; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000378:metabolism / Q000472:pathogenicity; D053038:Quorum Sensing / Q000187:drug effects*; D013211:Staphylococcus aureus / Q000187:drug effects / Q000378:metabolism / Q000472:pathogenicity